Bioxyne (ASX: BXN) has significantly upgraded its FY26 EBITDA guidance to AUD16.5-19 million on the back of record H1 FY2026 results, reporting revenue of AUD31.3 million—a substantial 149% increase year-on-year.
The company reported adjusted EBITDA of AUD8.3 million and a net profit after tax (NPAT) of AUD7.3 million.
Bioxyne additionally announced multiple strategic developments including capacity expansions and international market entries.
FY26 revenue guidance remains unchanged, projected to be between AUD65 million and AUD75 million.
The improvements in H1 margins contributed to this revised EBITDA outlook, a factor the company will focus on maintaining.
Expanded Manufacturing Capacity and MDMA Milestone
Bioxyne continued to scale its Good Manufacturing Practice (GMP) capabilities, successfully increasing its GMP clean room capacity by 100% and its storage capacity by 200%.
This expansion supports higher production volumes for its specialised product lines.
A major operational milestone was achieved with the successful production of the first Australian-made GMP-certified MDMA capsules.
This development is critical for Bioxyne's psychedelic product pipeline.
The company states its total revenue capacity for finished products now exceeds AUD250 million per year, with its Australian facility capable of producing up to 6 million MDMA pastilles per month.
International Expansion Gains Traction
Bioxyne made significant strides in its international market penetration, entering new territories including the UK, Germany, and LATAM.
Initial shipments to Germany alone generated AUD2.7 million in revenue during H1 FY26.
To further bolster its global footprint and enhance access to European capital, the company completed a dual listing on the Frankfurt Stock Exchange (PR8.F) on October 13, 2025.
Furthermore, development of a UK GMP manufacturing facility in the Scottish Borders is underway, with construction starting in February 2026 and completion targeted for June 2026.
This facility is supported by £0.848 million in non-dilutive funding from South of Scotland Enterprise, with licensing for the UK facility targeted for December 2026.
Strong Financial Position and Funding
At the end of H1 FY2026, Bioxyne reported a cash on hand balance of AUD7.6 million.
The company's net assets stood at AUD20.0 million, with total assets of AUD34.6 million and total liabilities of AUD14.5 million.
To meet anticipated demand, inventories increased to AUD11.7 million, and trade receivables were AUD5.8 million.
This strategic inventory build contributed to a negative operating cash flow of AUD1.29 million during the H1 FY26 period.
The previously mentioned £0.848 million non-dilutive funding for the UK GMP site provides additional financial support for its growth initiatives.
